This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nathan Sadeghi-Nejad

Contributor

Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.

Nathan Sadeghi-Nejad
By This Author:
« Back
Page 1 of 5

A Buysider's Preview of Biotech's Biggest Conference

By Nathan Sadeghi-Nejad

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

07:00AM 01/02/13

Breaking Up With Gilead Sciences

By Nathan Sadeghi-Nejad

Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.

07:00AM 12/17/12

Time For Common Sense Gun Control Has Arrived

By Nathan Sadeghi-Nejad

The tragedy in Newtown should bring gun owners and opponents together.

06:30AM 12/17/12

Sarepta Is Still A Buy: Recent Concerns Much Ado About Nothing

By Nathan Sadeghi-Nejad

Eteplirsen is a blockbuster drug for DMD, a view bolstered by Friday's 62-week data.

09:00AM 12/10/12

Thoughts on Bio-Pharma Investor Sentiment Going Into 2013

By Nathan Sadeghi-Nejad

Medical innovation is increasing but ever-escalating drug prices aren't sustainable.

07:00AM 12/03/12

Nate Sadeghi's 2012 Biotech Stock Report Card

By Nathan Sadeghi-Nejad

TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.

07:00AM 11/26/12

Seattle Genetics: A Short Thesis That's Been Right And Wrong

By Nathan Sadeghi-Nejad

Sales of the cancer drug Adcetris have fallen short but Seattle Genetics' stock price climbs higher.

07:00AM 11/12/12

Arena Pharma Is Still A Good Short

By Nathan Sadeghi-Nejad

A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.

07:00AM 11/05/12

Achillion Pharma Worthy of New Look

By Nathan Sadeghi-Nejad

The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.

08:16AM 10/31/12

United Therapeutics Could Lose The Battle For PAH Therapies

By Nathan Sadeghi-Nejad

An FDA decision expected this week could easily go against United Therapeutics.

07:00AM 10/22/12

« Back
Page 1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs